Metabolic changes during medical treatment of endometriosis: Nafarelin acetate versus danazol

K A Burry, Kenneth A. Burry, P E Patton, Phillip E. Patton, D R Illingworth, D. Roger Illingworth
American Journal of Obstetrics and Gynecology · 1989 · vol. 160(6) , pp. 1454–1461 · doi:10.1016/0002-9378(89)90870-3 · PMID:2525337 · W2066515003
article OA: closed CC0 ⤵ 27 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study investigated metabolic differences in women with endometriosis treated with nafarelin acetate versus danazol.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Danazol Endometriosis Genital Neoplasms, Female Gonadotropin-Releasing Hormone Lipids Pregnadienes Administration, Intranasal Adult Cholesterol Cholesterol Clinical Trials as Topic Danazol Danazol Double-Blind Method Endometriosis Endometriosis Endometriosis Female Genital Neoplasms, Female Genital Neoplasms, Female

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (27)

Cited by (27)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:09:10.744835+00:00
License: CC0 · commercial use OK